Clinical trials: Malignant Solid Tumours
Locally Advanced or Metastatic Solid Tumor
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid…
- Trial name
- NCT03601897
- Testing
- Rebastinib, Paclitaxel
- Where
- 14 sites in United States
- Volunteers
- 177 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Bystander Effect, Abscopal Effect
SBRT-based PArtial Tumor Irradiation of HYpoxic Segment
This study uses an unconventional radiotherapy schedule developed at our institute, consisting of a short course high-dose partial irradiation targeting exclusively the hypoxic segment of a bulky tumors, which in our preliminary…
- Conditions
- Bystander Effect, Abscopal Effect, Unresectable Malignant Solid Neoplasm, Bulky Tumors
- Trial name
- SBRT-PATHY (NCT04168320)
- Testing
- SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Klinikum Klagenfurt am Wörthersee
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
This phase II MATCH treatment trial evaluates the effectiveness of osimertinib (AZD9291) in treating patients with cancer that has certain genetic changes called EGFR mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT06303167
- Testing
- Biopsy Procedure, Biospecimen Collection, Echocardiography Test
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Advanced Malignant Solid Tumor
Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors
This study is being done to test the safety of elraglusib when taken once a day and to assess: How the body processes the drug (pharmacokinetics) Assess potential effects of the drug on heart rhythm Find the highest daily dose…
- Trial name
- NCT07714395
- Testing
- Elraglusib Oral Tablets
- Volunteers
- 100 people
- Sponsor
- Actuate Therapeutics Inc.
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy or immunotherapy regimens in treating patients with malignancies that have spread to other…
- Conditions
- Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma
- Trial name
- NCT02419495
- Testing
- Capecitabine, Carboplatin, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 221 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm, COVID-19 Infection
Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer
This study assesses the level of distress felt by cancer patients due to the coronavirus disease 2019 (COVID-19) pandemic. Researchers also want to learn if patients prefer to receive supportive care (palliative care) in person…
- Conditions
- Advanced Malignant Solid Neoplasm, COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT05058339
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Solid Tumors
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.
- Trial name
- NCT07229612
- Testing
- SHR-4298 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
This phase II trial tests how well craniospinal irradiation (CSI) using photon volumetric modulated arc radiotherapy (VMAT) works in treating patients with breast cancer or non-small cell lung cancer (NSCLC) that has spread from…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges
- Trial name
- NCT06910761
- Testing
- Biospecimen Collection, Craniospinal Irradiation, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Brain Metastasis, Meningeal Metastasis
QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors
QH101 is an allogeneic TCR-enhanced Vδ2 T cell therapy product engineered to express BTN protein-specific binding elements on the cell surface.
- Conditions
- Brain Metastasis, Meningeal Metastasis, Spinal Cord Metastasis
- Trial name
- NCT07656103
- Testing
- QH101 Cell Injection
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Immune-related Adverse Event, Malignant Solid Tumors
The Effect of Serum Ferritin in irAE
This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).
- Conditions
- Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia, Serum Ferritin
- Trial name
- NCT06702566
- Testing
- PD-1 and PD-L1 inhibitor, Targeted drugs, chemotherapy drugs
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Solid Tumours
An Extension Study of LON002 in Patients With Cancer
The purpose of this clinical trial is to evaluate the long term safety and efficacy of LON002.
- Trial name
- NCT02390986
- Testing
- LON002
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- LondonPharma Ltd.
Glioblastoma, Renal Cell Carcinoma
Dendritic Cell Vaccination for Patients with Solid Tumors
The aim of this study is to evaluate the immunogenicity and clinical efficacy of intradermal vaccination with autologous RNA-modified dendritic cells (DCs) - engineered to express the WT1 protein - in patients with limited spread…
- Conditions
- Glioblastoma, Renal Cell Carcinoma, Sarcomas, Breast Cancers
- Trial name
- NCT01291420
- Testing
- autologous dendritic cell vaccination
- Where
- Belgium
- Volunteers
- 48 people
- Sponsor
- University Hospital, Antwerp
Cancer, Survivorship
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
The primary purpose of this study is conduct a pilot study testing the study protocols, implementation program, and mixed-methods data collection.
- Conditions
- Cancer, Survivorship, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04337203
- Testing
- SHARE-S Implementation Program
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of pevonedistat when given together with irinotecan hydrochloride and temozolomide in treating patients with solid tumors, central nervous system (CNS) tumors, or lymphoma…
- Conditions
- Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma
- Trial name
- NCT03323034
- Testing
- Irinotecan, Pevonedistat, Temozolomide
- Where
- 20 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Oncology Group
Advanced Solid Tumor
Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors
To evaluate the safety and tolerability of combined administration of VSV injection solutions carrying different targets via multiple routes for treating advanced malignant solid tumors.
- Trial name
- NCT07656116
- Testing
- VSV injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Solid Tumours
A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours
This clinical trial will assess whether a medicine called artemether, currently used at a lower dose to treat malaria, could also be useful in treating cancer.
- Trial name
- LON002-002 (NCT02263950)
- Testing
- Artemether
- Where
- 2 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- LondonPharma Ltd.
Insomnia, Malignant Solid Neoplasm
THC Versus THC/CBD Versus Placebo to Improve Sleep Quality for Patients With Solid Organ Cancer and Insomnia
This phase II trial compares THC versus (vs.) THC with CBD vs. placebo to improve sleep quality for patients with solid organ cancer and insomnia.
- Trial name
- NCT07565974
- Testing
- Biospecimen Collection, Single Agent Therapy
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Mayo Clinic
Malignant Solid Tumor
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
- Trial name
- NCT02754141
- Testing
- BMS-986179, Nivolumab, rHuPH20
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 235 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in…
- Trial name
- NCT03459222
- Testing
- Relatlimab, Nivolumab, BMS-986205
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 229 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.